Suppression of immune regulatory cells with combined therapy of celecoxib and sunitinib in renal cell carcinoma

OBJECTIVE: To observe the the potential benefit of sunitinib in combination with cyclooxygenase-2(COX-2) inhibitor in renal cell carcinoma therapy. METHODS: 769-p cell lines were treated with sunitinib, celecoxib, or in combination at different concentrations respectively. We investigated the expres...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Qi, Guo, Jianming, Wang, Guomin, Chu, Yiwei, Hu, Xiaoyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352087/
https://www.ncbi.nlm.nih.gov/pubmed/27926489
http://dx.doi.org/10.18632/oncotarget.13774

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352087/
https://www.ncbi.nlm.nih.gov/pubmed/27926489
http://dx.doi.org/10.18632/oncotarget.13774

Ejemplares similares